These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 10976272)

  • 1. [The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors].
    Filatova LV; Gershanovich ML; Ketlinskiĭ SA; Simbirtsev AS
    Vopr Onkol; 2000; 46(3):278-84. PubMed ID: 10976272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors].
    Gershanovich ML; Ketlinskiĭ SA; Filatova LV; Danova LA; Korolenko VO; Simbirtsev AS
    Vopr Onkol; 1996; 42(6):13-8. PubMed ID: 9123895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapy.
    Gershanovich ML; Filatova LV; Ketlinsky SA; Simbirtsev AS
    Eur Cytokine Netw; 2001; 12(4):664-70. PubMed ID: 11781194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients.
    Gershanovich ML; Filatova LV; Ketlinsky SA; Simbirtsev AS
    Eur Cytokine Netw; 2001; 12(4):671-5. PubMed ID: 11781195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Betaleukin (human recombinant interleukin-1beta) for the prevention and correction of toxic leukopenia in chemotherapy of malignant neoplasms].
    Gershanovich ML; Filatova LV; Ketlinskiĭ SA; Simbirtsev AS
    Vopr Onkol; 1998; 44(2):181-6. PubMed ID: 9615823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Betaleukin (human recombinant interleukin-1 beta)--a new effective leukopoiesis stimulant and protector in the combined chemotherapy of malignant tumors].
    Gershanovich ML; Filatova LV; Ketlinskiĭ SA; Simbirtsev AS
    Vopr Onkol; 2000; 46(3):354-60. PubMed ID: 10976287
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
    Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
    Gustavson LE; Nadeau RW; Oldfield NF
    J Biol Response Mod; 1989 Aug; 8(4):440-9. PubMed ID: 2787839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
    Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
    Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
    Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.